Introduction to Cancer Metastasis provides, in one place, an overview of organ-specific cancer metastasis and the most common sites of cancer metastasis. Through specific chapters on individual primary cancers, their metastasis, and chapters on common metastatic sites, this volume comprehensively informs readers about the broader knowledge base in cancer metastasis. The process of metastasis is particularly responsible for making cancer so lethal. This volume explores both metastasis from sites of origin and common metastatic sites, thus increasing understanding of both perspectives.

This book focuses on the prophylactic potential of diet-derived factors in primary prevention of cancer. It is written by a group of highly reputed experts in the area of dietary agents and cancer chemoprevention. The translational potential of dietary factors from epidemiological, laboratory and clinical studies as prevention strategy in normal and risk populations is highlighted. The work presents options of routine inclusion of specific dietary regimens for prevention as well as therapeutic strategy for better management through adjuvant interventions in cancer treatment.

This, the second of two volumes on personalized medicine in lung cancer, touches upon the recent progress in targeted drug development based on genomics; emerging biomarkers and therapeutic targets such as EMT, cancer stem cells, and the tumor microenvironment; current personalized clinical management and radiation therapy for lung cancers; and the promise of epigenetics and next-generation sequencing for the advancements towards personalized therapy of lung cancer patients. With chapters on state-of-the-art therapies and technologies written by leading experts working to develop novel companion diagnosis tools for the personalized treatment of lung cancer patients, this volume brings readers up-to-date by presenting the current knowledge on the efforts to make personalized management of lung cancer patients a reality.

Resistance to therapies, both targeted and systemic, and metastases to distant organs are the underlying causes of breast cancer-associated mortality. The second edition of Breast Cancer Metastasis and Drug Resistance brings together some of the leading experts to comprehensively understand breast cancer: the factors that make it lethal, and current research and clinical progress. This volume covers the following core topics: basic understanding of breast cancer (statistics, epidemiology, racial disparity and heterogeneity), metastasis and drug resistance (bone metastasis, trastuzumab resistance, tamoxifen resistance and novel therapeutic targets, including non-coding RNAs, inflammatory cytokines, cancer stem cells, ubiquitin ligases, tumor microenvironment and signaling pathways such as TRAIL, JAK-STAT and mTOR) and recent developments in the field (epigenetic regulation, microRNAs-mediated regulation, novel therapies and the clinically relevant 3D models). Experts also discuss the advances in laboratory research along with their translational and clinical implications with an overarching goal to improve the diagnosis and prognosis, particularly that of breast cancer patients with advanced disease.

This volume comprehensively covers recent prrogress in breast cancer research. In an effort to successfully treat breast cancer, it is imperative to a) fully understand the disease with all its heterogeneity, b) understand the factors that influence the metastasis of breast cancer to distant organs making it lethal and c) understand the underlying processes that lead to the phenomenon of drug-resistance making the disease particularly incurable. The book explores all of these issues, including the phenomenon of epithelial-mesenchymal-transition, cancer stem cells as well as microRNAs in an attempt to better understand the disease in connection to its heterogeneity/metastasis/drug-resistance as well as to propose novel signaling pathways for therapeutic intervention. The profiling of tumors to molecularly classify breast cancers is also investigated so that customized targeted therapies can be developed.

The book is a collection of high-quality, peer-reviewed innovative research papers from the International Conference on Signals, Machines and Automation (SIGMA 2018) held at Netaji Subhas Institute of Technology (NSIT), Delhi, India. The conference offered researchers from academic and industry the opportunity to present their original work and exchange ideas, information, techniques and applications in the field of computational intelligence, artificial intelligence and machine intelligence. The book is divided into two volumes discussing a wide variety of industrial, engineering and scientific applications of the emerging techniques.

The book is a collection of high-quality, peer-reviewed innovative research papers from the International Conference on Signals, Machines and Automation (SIGMA 2018) held at Netaji Subhas Institute of Technology (NSIT), Delhi, India. The conference offered researchers from academic and industry the opportunity to present their original work and exchange ideas, information, techniques and applications in the field of computational intelligence, artificial intelligence and machine intelligence. The book is divided into two volumes discussing a wide variety of industrial, engineering and scientific applications of the emerging techniques.

Resistance to therapies, both targeted and systemic, and metastases to distant organs are the underlying causes of breast cancer-associated mortality. The second edition of Breast Cancer Metastasis and Drug Resistance brings together some of the leading experts to comprehensively understand breast cancer: the factors that make it lethal, and current research and clinical progress. This volume covers the following core topics: basic understanding of breast cancer (statistics, epidemiology, racial disparity and heterogeneity), metastasis and drug resistance (bone metastasis, trastuzumab resistance, tamoxifen resistance and novel therapeutic targets, including non-coding RNAs, inflammatory cytokines, cancer stem cells, ubiquitin ligases, tumor microenvironment and signaling pathways such as TRAIL, JAK-STAT and mTOR) and recent developments in the field (epigenetic regulation, microRNAs-mediated regulation, novel therapies and the clinically relevant 3D models). Experts also discuss the advances in laboratory research along with their translational and clinical implications with an overarching goal to improve the diagnosis and prognosis, particularly that of breast cancer patients with advanced disease.

This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer-statistics and epidemiology of lung cancer-along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer-immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies.

This, the second of two volumes on personalized medicine in lung cancer, touches upon the recent progress in targeted drug development based on genomics; emerging biomarkers and therapeutic targets such as EMT, cancer stem cells, and the tumor microenvironment; current personalized clinical management and radiation therapy for lung cancers; and the promise of epigenetics and next-generation sequencing for the advancements towards personalized therapy of lung cancer patients. With chapters on state-of-the-art therapies and technologies written by leading experts working to develop novel companion diagnosis tools for the personalized treatment of lung cancer patients, this volume brings readers up-to-date by presenting the current knowledge on the efforts to make personalized management of lung cancer patients a reality.

This book focuses on the prophylactic potential of diet-derived factors in primary prevention of cancer. It is written by a group of highly reputed experts in the area of dietary agents and cancer chemoprevention. The translational potential of dietary factors from epidemiological, laboratory and clinical studies as prevention strategy in normal and risk populations is highlighted. The work presents options of routine inclusion of specific dietary regimens for prevention as well as therapeutic strategy for better management through adjuvant interventions in cancer treatment.